186 related articles for article (PubMed ID: 1379385)
1. Availability of the B beta(15-21) epitope on cross-linked human fibrin and its plasmic degradation products.
Chen F; Haber E; Matsueda GR
Thromb Haemost; 1992 Mar; 67(3):335-40. PubMed ID: 1379385
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of monoclonal antifibrin antibodies by their binding to human blood clots.
Liau CS; Haber E; Matsueda GR
Thromb Haemost; 1987 Feb; 57(1):49-54. PubMed ID: 3590080
[TBL] [Abstract][Full Text] [Related]
3. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
[TBL] [Abstract][Full Text] [Related]
4. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
[TBL] [Abstract][Full Text] [Related]
5. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
Weitz JI; Leslie B; Ginsberg J
J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
[TBL] [Abstract][Full Text] [Related]
6. Accessibility of epitopes on fibrin clots and fibrinogen gels.
Procyk R; Kudryk B; Callender S; Blombäck B
Blood; 1991 Apr; 77(7):1469-75. PubMed ID: 1706954
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies.
Raut S; Gaffney PJ
Thromb Haemost; 1996 Jul; 76(1):56-64. PubMed ID: 8819252
[TBL] [Abstract][Full Text] [Related]
8. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a monoclonal antibody specific to the amino terminus of the alpha-chain of human fibrin.
Mao SJ; Rechtin AE; Krstenansky JL; Jackson RL
Thromb Haemost; 1990 Jun; 63(3):445-8. PubMed ID: 2402748
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
[TBL] [Abstract][Full Text] [Related]
11. Cloning of the complete coding sequence of rat fibrinogen B beta chain cDNA: interspecies conservation of fibrin beta 15-42 primary structure.
Courtney MA; Bunce LA; Neroni LA; Simpson-Haidaris PJ
Blood Coagul Fibrinolysis; 1994 Aug; 5(4):487-96. PubMed ID: 7841303
[TBL] [Abstract][Full Text] [Related]
12. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN.
Dempfle CE; Dollman M; Lill H; Puzzovio D; Dessauer A; Heene DL
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):79-86. PubMed ID: 8457657
[TBL] [Abstract][Full Text] [Related]
13. The study of fibrin polymerization with monoclonal antibodies.
Lugovskoi EV; Makogonenko EM; Chudnovets VS; Derzskaya SG; Gogolinskaya GK; Kolesnikova IN; Bukhanevich AM; Sitak IN; Lyashko ED; Komissarenko SV
Biomed Sci; 1991; 2(3):249-56. PubMed ID: 1751757
[TBL] [Abstract][Full Text] [Related]
14. Validation, calibration, and specificity of quantitative D-dimer assays.
Dempfle CE
Semin Vasc Med; 2005 Nov; 5(4):315-20. PubMed ID: 16302152
[TBL] [Abstract][Full Text] [Related]
15. Degradation of cross-linked fibrin by human leukocyte proteases.
Francis CW; Marder VJ
J Lab Clin Med; 1986 Apr; 107(4):342-52. PubMed ID: 3514776
[TBL] [Abstract][Full Text] [Related]
16. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Carroll RC; Lockhart MS; Taylor FB
J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
[TBL] [Abstract][Full Text] [Related]
17. The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests.
Brenner B; Francis CW; Marder VJ
J Lab Clin Med; 1989 Jun; 113(6):682-8. PubMed ID: 2732616
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies of predetermined specificity for fibrin: a rational approach to monoclonal antibody production.
Hui KY; Haber E; Matsueda GR
Hybridoma; 1986; 5(3):215-22. PubMed ID: 2429911
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
20. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond.
Bini A; Itoh Y; Kudryk BJ; Nagase H
Biochemistry; 1996 Oct; 35(40):13056-63. PubMed ID: 8855941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
